ANZUP1802
21 Dec 2020
Trial Summary
The research project is testing a new treatment for participants with locally advanced or metastatic non-clear cell kidney cancer. The new treatment involves a drug called Cabozantinib (also known as Cabometyx). This drug has been used previously in many cancers, including clear cell kidney cancer and thyroid cancer.
Acronym:
UNICAB
ACTRN/NCT /ethics:
NCT03685448
Scientific title:
ANZUP – Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
Sponsor / Cooperative group:
ANZUP
Trial & Patient Characteristics
| Cancer Type | Kidney |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2019-04-11 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | - |
| Recruitment Status | Recruitment on Hold |